StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research report report published on Monday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Performance
EVOK stock opened at $5.65 on Monday. The company has a market capitalization of $4.64 million, a PE ratio of -0.35 and a beta of 0.36. Evoke Pharma has a one year low of $3.54 and a one year high of $17.88. The company’s 50 day moving average price is $4.99 and its two-hundred day moving average price is $5.52.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%. The business had revenue of $2.55 million during the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Recommended Stories
- Five stocks we like better than Evoke Pharma
- How to Evaluate a Stock Before Buying
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- Stock Sentiment Analysis: How it Works
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Market Cap Calculator: How to Calculate Market Cap
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
